Physician profile
Chloe Ward
NPI 1861843831
$4,386.68
in general payments reported to CMS, 2019-2025
20 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $815 · 2023: $1,744 · 2024: $818 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.42 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $543.09 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $541.99 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $422.79 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $418.61 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $339.55 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.53 | 2021-2024 | Caplyta |
| Neuronetics, INC. | $289.38 | 2022-2023 | Neurostar Tms Therapy System |
| Lundbeck LLC | $223.44 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $206.17 | 2021-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $171.28 | 2021-2024 | Trintellix |
| Corium, LLC | $131.88 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $96.82 | 2021-2022 | |
| Almatica Pharma LLC | $21.97 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $21.28 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.04 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.98 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $17.42 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.37 | 2021 | |
| Noven Therapeutics, LLC | $14.67 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.